ABIVAX Société Anonyme マネジメント

マネジメント基準チェック /24

ABIVAX Société Anonymeの CEO はMarc M. de Garidelで、 May2023年に任命され、の在任期間は 1.42年です。の年間総報酬は€ 793.97Kで、 45.3%給与と54.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.06%を直接所有しており、その価値は$ 383.78K 。経営陣と取締役会の平均在任期間はそれぞれ1.3年と3.2年です。

主要情報

Marc M. de Garidel

最高経営責任者

€794.0k

報酬総額

CEO給与比率	45.3%
CEO在任期間	1.4yrs
CEOの所有権	0.06%
経営陣の平均在職期間	1.3yrs
取締役会の平均在任期間	3.2yrs

経営陣の近況

Recent updates

CEO報酬分析

ABIVAX Société Anonyme の収益と比較して、Marc M. de Garidel の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-€177m
Mar 31 2024	n/a	n/a	-€163m
Dec 31 2023	€794k	€359k	-€148m

報酬と市場: Marc M.の総報酬 ($USD 857.05K ) は、 US市場 ($USD 3.18M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Marc M.の報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Marc M. de Garidel (66 yo)

1.4yrs

在職期間

€793,971

報酬

Mr. Marc M. P. de Garidel, M.B.A., serves as Director of Claris Biotherapeutics, Inc. He serves as CEO at ABIVAX Société Anonyme since May 5, 2023 amd serves as its Director. He had been its Interim Chair...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Marc M. de Garidel	CEO & Director	1.4yrs	€793.97k	0.060% $ 383.8k
Philippe Pouletty	Founder & Director	no data	€35.00k	0.43% $ 2.8m
Didier Blondel	EVP, CFO & Board Secretary	7.8yrs	データなし	0.00059% $ 3.8k
Didier Scherrer	Chief Scientific Officer	1.2yrs	データなし	0.057% $ 359.9k
Patrick Malloy	Senior Vice President of Investor Relations	1.2yrs	データなし	データなし
Ida Hatoum	Chief People & Compliance Officer	1.3yrs	データなし	データなし
Pierre Courteille	Chief Business Officer	no data	データなし	0% $ 0
Jerome Denis	Executive Vice President of Process Development & Manufacturing	1.1yrs	データなし	データなし
Michael Ferguson	Chief Commercial Officer	1.5yrs	データなし	データなし
Ana Sharma	VP & Global Head of Quality	less than a year	データなし	データなし
Hema Keshava	Senior Vice President of Finance	no data	データなし	データなし
Chris Rabbat	VP & Global Head of Medical Affairs	no data	データなし	データなし

1.3yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: AAVX.Fの経営陣は経験豊富とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Marc M. de Garidel	CEO & Director	1.4yrs	€793.97k	0.060% $ 383.8k
Philippe Pouletty	Founder & Director	10.8yrs	€35.00k	0.43% $ 2.8m
Sylvie Gregoire	Chair of the Board	less than a year	データなし	データなし
Christian Trepo	Member of Scientific Advisory Board	no data	データなし	データなし
Lawrence Stanberry	Member of Scientific Advisory Board	no data	データなし	データなし
Troy Ignelzi	Independent Director	1.3yrs	€44.33k	データなし
Christoph Huber	Member of Scientific Advisory Board	no data	データなし	データなし
Claude Bertrand	Member of Scientific Advisory Board	5yrs	€4.94k	データなし
Luc Teyton	Member of Scientific Advisory Board	no data	データなし	データなし
June Lee	Independent Director	1.3yrs	€35.24k	データなし
Corinna Bonsen-Thomas	Independent Non-Executive Director	7.3yrs	€135.16k	0% $ 0
Ian McGowan	Chairman of Scientific Advisory Board	6.3yrs	データなし	データなし

3.2yrs

平均在職期間

63.5yo

平均年齢

経験豊富なボード: AAVX.Fの取締役会は経験豊富であると考えられます ( 3.2年の平均在任期間)。

ABIVAX Société Anonyme マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Abivax SA Announces Board Observer & Advisor Appointments

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24